MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA), a leader in the development of medical devices for soft tissue reconstruction, has made a significant stride in surgical innovation with the recent U.S. launch of its LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices. These devices represent a breakthrough in hernia repair technology, offering a novel approach to mesh fixation that could redefine standards of care for over 1.2 million hernia procedures performed annually in the United States.
The LIQUIFIX devices are distinguished as the only FDA-approved options that utilize liquid anchors to secure mesh and approximate peritoneal tissue, eliminating the need for traditional mechanical fasteners such as tacks, sutures, or staples. This method of fixation is designed to minimize tissue trauma, potentially reducing the risk of complications often associated with hernia repair surgeries.
Inguinal hernias, the most common type of hernia surgery in the U.S., have traditionally been repaired using methods that can inadvertently damage sensitive areas known colloquially as the “triangle of doom” and “triangle of pain.” These regions contain critical arteries, veins, and nerves, where mechanical fixation methods pose a risk of major injuries, leading to chronic postoperative pain. The LIQUIFIX devices aim to mitigate these risks by providing a safer, more precise means of securing the surgical mesh without penetrating patient tissue.
Antony Koblish, President and CEO of TELA Bio, emphasized the alignment of the LIQUIFIX devices with the company’s mission to preserve and restore patient anatomy. “This novel device is a natural addition to our fast-growing commercial portfolio,” Koblish said, expressing optimism about the potential of these products to advance hernia repair techniques across the U.S.
The effectiveness and safety of the LIQUIFIX devices have been attested by practitioners such as Mr. Paul Wilson, a Consultant General Surgeon in the United Kingdom, who reported significant patient benefits including reduced postoperative pain and chronic discomfort. “This has been a game-changer for me,” Wilson stated, highlighting the device’s ease of use and impressive fixation strength.
Manufactured by Advanced Medical Solutions Limited (AMS), a global leader in tissue-healing technologies based in the U.K., the LIQUIFIX products have shown strong performance in European and other international markets over the past three years. The collaboration between AMS and TELA Bio aims to replicate this success in the U.S., leveraging TELA Bio’s specialty salesforce and focus on innovative technologies.
Chris Meredith, CEO of AMS, expressed enthusiasm for the partnership with TELA Bio and the potential for increased adoption of the LIQUIFIX products in the U.S. market. As TELA Bio and AMS work together to promote this cutting-edge technology, the LIQUIFIX devices stand poised to revolutionize hernia repair, offering surgeons a new tool to improve outcomes and enhance patient recovery.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.